Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute STEMI

Condition:   Myocardial Infarction
Intervention:   Procedure: STEMI treated with primary PCI
Sponsors:   Gachon University Gil Medical Center;   Soon Chun Hyang University;   Sejong General Hospital;   Inha University Hospital
Completed - verified June 2016

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Angioplasty, Balloon, Coronary;   Platelet Aggregation Inhibitors
Interventions:   Drug: Prasugrel;   Drug: Ticagrelor
Sponsor:   Faculty Hospital Kralovske Vinohrady
Active, not recruiting - verified June 2016

The Application of Multichannel ECG Analytic System in Cardiovascular Diseases

Condition:   Multichannel ECG System
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified June 2016

Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

Conditions:   Hypogonadism;   Acute Myocardial Infarction: Rehabilitation Phase
Interventions:   Drug: Testosterone;   Drug: Normal Saline
Sponsor:   Texas Tech University Health Sciences Center
Not yet recruiting - verified June 2016

The Effect of Remote Ischemic Preconditioning on Major Organ Function in Patients With Coronary Artery Disease Undergoing Orthopedic Surgery

Conditions:   Angina Pectoris;   Myocardial Infarction
Interventions:   Procedure: Remote ischemic preconditioning;   Procedure: Sham control
Sponsor:   Seoul National University Hospital
Not yet recruiting - verified June 2016

Angio-based Flow Fractional Reserve to Predict Adverse Events After Stent Implantation

Conditions:   Prognosis;   Stents
Intervention:   Other: angio-based FFR estimation
Sponsor:   University Hospital of Ferrara
Recruiting - verified June 2016

Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?

Condition:   Pneumonia
Interventions:   Drug: Vitamin D3 supplementation;   Biological: Peripheral blood and induced sputum sampling;   Radiation: chest CT scans;   Other: Symptom questionnaire
Sponsor:   Queen Mary University of London
Not yet recruiting - verified June 2016

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Not yet recruiting - verified June 2016

Global CMR Registry

Condition:   Cardiovascular Diseases
Intervention:   Procedure: Cardiovascular Magnetic Resonance Imaging
Sponsor:   Society for Cardiovascular Magnetic Resonance
Active, not recruiting - verified June 2016

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)

Conditions:   Acute Myocardial Infarction;   Percutaneous Coronary Intervention;   Major Adverse Cardiovascular Events;   Bleeding
Interventions:   Procedure: Percutaneous coronary intervention;   Drug: Dual-antiplatelet therapy;   Procedure: Percutaneous coronary intervention;   Drug: Dual-antiplatelet therapy
Sponsors:   Seoul St. Mary's Hospital;   The Catholic University of Korea;   Chonnam National University;   AstraZeneca
Recruiting - verified June 2016

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

Condition:   Antiplatelet Drugs
Interventions:   Drug: Aspirin only;   Drug: No antiplatelet therapy
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified June 2016

Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study)

Conditions:   Atrial Fibrillation;   Aldosterone
Intervention:  
Sponsor:   University Hospital, Caen
Recruiting - verified June 2016

Controlling And Lowering Blood Pressure With the MobiusHDTM Device

Condition:   Hypertension
Interventions:   Device: MobiusHD;   Other: Sham Implantation
Sponsor:   Vascular Dynamics, Inc.
Not yet recruiting - verified June 2016

Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions

Condition:   Percutaneous Transluminal Coronary Angioplasty
Intervention:   Other: 5 year Follow-up
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified June 2016

Naloxegol Health Outcomes PASS

Condition:   Opioid Induced Constipation
Interventions:   Drug: naloxegol;   Drug: non-PAMORA laxative
Sponsor:   AstraZeneca
Not yet recruiting - verified June 2016

Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study

Conditions:   Severe and Symptomatic Aortic Stenosis;   Stable Coronary Disease
Intervention:   Procedure: TAVI procedure
Sponsor:   University Hospital, Montpellier
Not yet recruiting - verified June 2016

Randomized Anticoagulation Trial in Opcab (RATIO)

Condition:   Ischemic Heart Disease
Intervention:   Drug: Heparin
Sponsor:   Azienda Ospedaliera di Lecco
Not yet recruiting - verified June 2016

APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

Conditions:   Acute Coronary Syndrome;   Atrial Fibrillation;   Coronary Artery Disease
Interventions:   Other: Dual Therapy;   Other: Triple Therapy
Sponsors:   Klinikum der Universitaet Muenchen;   Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK);   Technische Universität München;   Helmholtz Zentrum München;   University of Göttingen;   University of München;   University Medicine Greifswald
Not yet recruiting - verified May 2016

Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)

Condition:   Supraventricular Tachycardia
Intervention:   Other: No Intervention
Sponsor:   Lakeland Health
Active, not recruiting - verified June 2016

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Not yet recruiting - verified June 2016

Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Conditions:   Acute Coronary Syndromes;   ST Elevation Myocardial Infarction
Interventions:   Drug: Chewing Ticagrelor;   Drug: Oral Ticagrelor
Sponsor:   Sheba Medical Center
Recruiting - verified April 2016

Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators

Conditions:   Asthma: [Nos] or [Attack];   Major Depressive Disorder
Interventions:   Drug: Escitalopram;   Drug: Venlafaxine XR;   Drug: Bupropion XR;   Drug: Sertraline;   Drug: Mirtazapine;   Drug: Buspirone;   Drug: Quetiapine;   Drug: Aripiprazole;   Drug: Lithium
Sponsors:   University of Texas Southwestern Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   University at Buffalo
Recruiting - verified June 2016

Assessing the Capability of Cardiogoniometry (CGM) to Detect Changes in Cardiac Resynchronisation Therapy Device Settings

Condition:   Heart Failure
Intervention:   Device: Cardiogoniometry
Sponsor:   Hull and East Yorkshire Hospitals NHS Trust
Recruiting - verified February 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified June 2016

A Study of the ReCor Medical Paradise System in Clinical Hypertension

Conditions:   Hypertension;   Vascular Diseases
Interventions:   Device: The Paradise® Renal Denervation Ultrasound System;   Device: Sham Procedure
Sponsor:   ReCor Medical, Inc.
Recruiting - verified March 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified June 2016

Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice

Conditions:   Arterial Occlusive Diseases;   Cardiovascular Diseases;   Coronary Artery Disease;   Coronary Disease
Intervention:   Device: Bioresorbable Vascular Scaffold
Sponsors:   Duk-Woo Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified June 2016

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Conditions:   Coronary Disease;   Shock, Cardiogenic;   Renal Failure;   Stroke;   Brain Injury;   Aortic Valve Disease
Interventions:   Drug: Byetta (Lilly, Exenatide);   Drug: Conoxia (AGA, oxygen);   Drug: 20% Human Albumin
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified June 2016

Testing a Community Intervention to Increase Aspirin Use

Conditions:   Myocardial Infarction;   Stroke
Interventions:   Other: Mass Media plus clinic intervention.;   Other: Media
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified June 2016

IRIS-Onyx Cohort in the IRIS-DES Registry

Conditions:   Coronary Artery Disease;   Arterial Occlusive Diseases;   Cardiovascular Diseases;   Percutaneous Transluminal Angioplasty
Intervention:   Device: Onyx Drug Eluting Stent group
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Medtronic Korea Co., Ltd.
Recruiting - verified June 2016

Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock

Condition:   Cardiogenic Shock
Intervention:   Drug: adrenaline
Sponsors:   Niguarda Hospital;   Papa Giovanni XXIII Hospital
Recruiting - verified June 2016

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions:   Arterial Occlusive Diseases;   Coronary Artery Disease;   Coronary Disease;   Arteriosclerosis;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Acute Coronary Syndrome
Interventions:   Drug: PZ-128;   Drug: Placebo
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   RTI International;   Inova Fairfax Hospital;   University of Massachusetts, Worcester
Recruiting - verified June 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified June 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified June 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified June 2016

Novel Biomarkers of Thrombotic Risk

Condition:   Myocardial Infarction
Intervention:  
Sponsors:   University of Vermont;   Janssen Research & Development, LLC
Recruiting - verified June 2016

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified June 2016

Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

Conditions:   Diabetes Mellitus;   Acute Coronary Syndrome;   Coronary Artery Disease
Interventions:   Drug: Novel strategy Aspirin;   Drug: Conventional strategy Aspirin
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Bayer
Recruiting - verified June 2016

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany and the UK: REACT-AF2

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   IMS Health;   Oxon Epidemiology
Active, not recruiting - verified June 2016

Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Condition:   Coronary Artery Disease
Interventions:   Device: HeartMate PHP;   Device: Abiomed Impella® Recover® LP 2.5
Sponsors:   Thoratec Corporation;   St. Jude Medical
Recruiting - verified June 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified May 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified March 2016

The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry

Conditions:   Aortic Valve Stenosis;   Cardiovascular Diseases;   Heart Valve Diseases;   Bicuspid
Intervention:   Procedure: transcatheter aortic valve replacement
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

Condition:   Hypertension
Interventions:   Device: Renal Denervation (Vessix);   Device: Renal Angiography
Sponsor:   Boston Scientific Corporation
Recruiting - verified June 2016

High Fidelity Simulation vs Standard Teaching Training of Cardiac Resuscitation

Condition:   Cardiac Arrest
Interventions:   Device: Laerdal®;   Behavioral: huma patient based training;   Behavioral: traditionally teaching
Sponsor:   University of Monastir
Completed - verified June 2016

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

Condition:   Graft-Versus-Host Disease
Intervention:   Biological: MSC
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2016

The Asian Transcatheter Aortic Valve Replacement Registry

Conditions:   Aortic Valve Stenosis;   Aortic Diseases
Intervention:   Device: transcatheter aortic valve replacement
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified June 2016

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

Conditions:   Dilated Cardiomyopathy (DCM);   Ischemic Cardiomyopathy;   Nonischemic Cardiomyopathy;   Heart Failure
Intervention:   Biological: Allogeneic Cardiosphere-Derived Cells (CDCs)
Sponsors:   Capricor Inc.;   Cedars-Sinai Medical Center;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified June 2016

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Condition:   Cardiogenic Shock
Intervention:   Device: HeartMate PHP
Sponsors:   Thoratec Corporation;   St. Jude Medical
Recruiting - verified June 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified June 2016

Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   Instituto Mexicano del Seguro Social
Recruiting - verified June 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2016

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

Condition:   ST Segment Elevation Myocardial Infarction.
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   Gyeongsang National University Hospital;   Chinese PLA General Hospital;   Chungnam National University Hospital;   Pusan National University Yangsan Hospital;   National University Heart Centre, Singapore;   Ulsan University Hospital;   Kyungpook National University;   Samsung Changwon Hospital;   Kyunghee University Medical Center;   Chungbuk National University Hospital;   Chonnam National University Hospital;   Seoul National University Bundang Hospital
Recruiting - verified June 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily;   Drug: Standard therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified June 2016

Atrial Fibrillation Detected by ELR and Holter Recording, a Comparison in Patients With Ischemic Stroke or TIA

Conditions:   Stroke;   Ischaemic Stroke;   Atrial Fibrillation;   Supra Ventricular Extra Systoles
Intervention:  
Sponsors:   University of Aarhus;   Hospitalsenheden Vest
Recruiting - verified June 2016

Non Invasive dP/dt to Detect an Acute Ischemic Myocardial Dysfunction in Emergency Department

Condition:   Acute Myocardial Ischemia
Intervention:  
Sponsor:   University of Monastir
Active, not recruiting - verified June 2016

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified June 2016

COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients

Condition:   NSTEMI
Interventions:   Drug: Colchicine;   Drug: Placebo
Sponsors:   Tel-Aviv Sourasky Medical Center;   Tel Aviv Medical Center
Withdrawn - verified June 2016

Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Troponin
Intervention:  
Sponsors:   Minneapolis Medical Research Foundation;   Abbott Diagnostics Division;   Hennepin County Medical Center, Minneapolis
Active, not recruiting - verified June 2016

IRIS-PREMIER REGISTRY

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Coronary Disease;   Heart Diseases
Intervention:   Device: Promus PREMIER
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Boston Scientific Korea Co. Ltd
Recruiting - verified June 2016

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

Conditions:   Hypertension;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2016

DESyne in Routine Clinical Practice

Conditions:   Angioplasty, Transluminal, Percutaneous Coronary;   Coronary Artery Disease
Intervention:   Device: DeSyne drug eluting stent group
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Amg Korea Co. Ltd.
Recruiting - verified June 2016

Orsiro™ Drug Eluting Stent in Routine Clinical Practice

Conditions:   Angioplasty, Transluminal, Percutaneous Coronary;   Coronary Artery Disease
Intervention:   Device: Orsiro™ Drug Eluting Stent group
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Biotronik Korea Co., Ltd
Recruiting - verified June 2016

XIENCE Xpedition/Alpine in Routine Clinical Practice

Conditions:   Percutaneous Transluminal Coronary Angioplasty;   Coronary Artery Disease
Intervention:   Device: XIENCE Xpedition/Alpine
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Abbott
Recruiting - verified June 2016

Drug-Eluting Balloon Registry in Routine Clinical Practice

Conditions:   Coronary Artery Disease;   Angioplasty, Balloon
Intervention:   Device: Balloon angioplasty
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   B. Braun Korea Co., Ltd.
Recruiting - verified June 2016

Asan Multivessel Registry

Condition:   Coronary Artery Disease
Intervention:   Other: Treatment
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified June 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified June 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified June 2016

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

Condition:   Stable Coronary Artery Disease (CAD), Myocardial Infarction
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified June 2016

Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery

Conditions:   High Risk Non-cardiac Surgery;   Death;   Delirium;   Kidney Injury;   Myocardial Infarction;   Respiratory Failure;   Postoperative Infection
Intervention:   Other: Observational study
Sponsors:   University of Manitoba;   Canadian Anesthesia Research Foundation
Recruiting - verified June 2016

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Active, not recruiting - verified June 2016

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Conditions:   Coronary Artery Disease;   Stable Angina;   Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Aspirin;   Drug: Placebo - Ticagrelor;   Drug: Placebo - Aspirin
Sponsors:   Deutsches Herzzentrum Muenchen;   AstraZeneca
Recruiting - verified June 2016

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified June 2016

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified June 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2016

DXR Stent(Previous Cilotax) Implantation Registry

Condition:   Coronary Artery Diseases
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Cardiotec Corporation
Recruiting - verified June 2016

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myeldysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia;   Bone Marrow Diseases;   Neutropenia;   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Clofarabine;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Celgene Corporation
Completed - verified March 2016

Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions

Condition:   Coronary Heart Disease
Interventions:   Device: Drug eluting balloon;   Device: Drug eluting stent
Sponsors:   University Hospital, Basel, Switzerland;   Clinical Trial Unit, University Hospital Basel, Switzerland
Recruiting - verified June 2016

Remote Ischemic Preconditioning Prior to Vascular Surgery

Conditions:   Peripheral Arterial Disease;   Vascular Surgery
Interventions:   Procedure: Preconditioning;   Procedure: Control
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified June 2016

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Condition:   Coronary Artery Disease
Intervention:   Device: percutaneous coronary intervention
Sponsors:   Seung-Jung Park;   Abbott;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2016

The IRIS-Resolute Integrity (IRIS-Integrity)

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Medtronic
Active, not recruiting - verified June 2016

Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Abbott
Active, not recruiting - verified June 2016

Evaluation of Effectiveness and Safety of NOBORI Stent

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Terumo Corporation
Active, not recruiting - verified June 2016

Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Dio
Active, not recruiting - verified June 2016

Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Boston Scientific Corporation
Active, not recruiting - verified June 2016

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Conditions:   Myocardial Infarction;   STEMI
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsors:   Stiftung Institut fuer Herzinfarktforschung;   Daiichi Sankyo Inc.
Completed - verified June 2016

German Chest Pain Unit (CPU)-Register

Condition:   Chest Pain
Intervention:  
Sponsor:   Stiftung Institut fuer Herzinfarktforschung
Completed - verified June 2016

Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Conditions:   Coronary Artery Disease;   Percutaneous Transluminal Coronary Angioplasty
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Biological: MNC;   Biological: AC 133;   Biological: Control
Sponsor:   Royan Institute
Completed - verified July 2010

German Ablation Quality-Register

Condition:   Arrhythmia
Intervention:  
Sponsor:   Stiftung Institut fuer Herzinfarktforschung
Completed - verified June 2016

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)

Condition:   Coronary Artery Disease
Interventions:   Procedure: Cypher, xience, Endeavor, Taxus;   Drug: optimal medical therapy
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

Condition:   Coronary Artery Disease
Interventions:   Device: XIENCE V;   Device: CYPHER
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Active, not recruiting - verified June 2016

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions:   Severe, Refractory Asthma;   Airway Inflammation;   Airflow Obstruction
Intervention:   Drug: Pioglitazone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2016

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions:   MDS;   Immunodeficiency;   GATA2
Interventions:   Drug: Cyclophosphamide (CTX, Cytoxan);   Drug: Fludarabine(Fludara,Berlex Laboratories);   Procedure: Total Body Irradiation (TBI);   Procedure: Allogeneic HSC;   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified June 2016

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function

Conditions:   Ischemia;   Myocardial Infarction;   Ischemic Heart Disease
Intervention:  
Sponsors:   Yale University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2016

Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Yale University
Withdrawn - verified June 2016

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2016

The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes

Conditions:   Prediabetes;   Insulin Resistance;   Metabolic Syndrome
Interventions:   Behavioral: Almonds in a calorie controlled diet;   Behavioral: Nut free diet
Sponsors:   University of Medicine and Dentistry of New Jersey;   Almond Board of California
Completed - verified June 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions:   Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention:   Drug: G-CSF
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   New York University and New York Genome Center
Recruiting - verified June 2016